Functional assessments in repeat-dose toxicity studies: the art of the possible
Abstract
Clinical and nonclinical safety liabilities remain a major cause of adverse
* Corresponding authors
a
Global Safety Assessment, AstraZeneca R&D, Alderley Park, Cheshire SK10 4TG, United Kingdom
E-mail:
will.redfern@astrazeneca.com
Clinical and nonclinical safety liabilities remain a major cause of adverse
Fetching data from CrossRef.
This may take some time to load.
Loading related content